ATEA PHARMACEUTICALS INC's ticker is AVIR and the CUSIP is 04683R106. A total of 126 filers reported holding ATEA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.50 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,720,320 | -18.8% | 4,573,440 | +1.2% | 0.00% | – |
| Q2 2023 | $16,895,820 | +9.9% | 4,517,599 | -1.5% | 0.00% | – |
| Q1 2023 | $15,367,057 | -47.5% | 4,587,181 | -24.7% | 0.00% | -100.0% |
| Q4 2022 | $29,290,601 | -32.1% | 6,089,522 | -19.7% | 0.00% | 0.0% |
| Q3 2022 | $43,155,000 | -15.3% | 7,584,256 | +5.6% | 0.00% | 0.0% |
| Q2 2022 | $50,980,000 | +4.9% | 7,180,285 | +6.7% | 0.00% | 0.0% |
| Q1 2022 | $48,584,000 | -6.0% | 6,729,203 | +16.4% | 0.00% | 0.0% |
| Q4 2021 | $51,690,000 | -71.5% | 5,781,882 | +11.6% | 0.00% | -80.0% |
| Q3 2021 | $181,608,000 | +86.4% | 5,179,955 | +14.2% | 0.01% | +150.0% |
| Q2 2021 | $97,437,000 | +42.6% | 4,536,163 | +309.8% | 0.00% | 0.0% |
| Q1 2021 | $68,351,000 | +50.8% | 1,106,905 | +2.1% | 0.00% | +100.0% |
| Q4 2020 | $45,312,000 | – | 1,084,527 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | $17,648,000 | 2.07% |
| EcoR1 Capital, LLC | 6,340,639 | $45,019,000 | 1.55% |
| CM Management, LLC | 200,000 | $1,420,000 | 1.51% |
| K2 PRINCIPAL FUND, L.P. | 1,606,059 | $11,403,000 | 1.26% |
| Cormorant Asset Management, LP | 1,547,181 | $10,985,000 | 0.83% |
| Privium Fund Management (UK) Ltd | 61,284 | $435,000 | 0.49% |
| Atom Investors LP | 30,911 | $219,000 | 0.10% |
| FEDERATED HERMES, INC. | 3,588,131 | $25,476,000 | 0.07% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 347,612 | $2,468,000 | 0.06% |
| BALYASNY ASSET MANAGEMENT L.P. | 1,799,507 | $12,777,000 | 0.04% |